
|Articles|September 14, 2015
- Squamous NSCLC
- Volume 1
- Issue 1
Evolving Paradigms in Squamous NSCLC: Conclusion
Author(s)Staff Writer
Squamous cell lung cancer represents a distinct molecular pathologic NSCLC with unmet therapeutic needs, especially after failure of first-line platinum-based doublet chemotherapy.
Advertisement
This article is Part III of a series. View parts I and II:Evolving Paradigms in Squamous NSCLC> >
Articles in this issue
about 10 years ago
Cancer Immunotherapy: Evolving Treatment Options in Squamous NSCLCabout 10 years ago
Evolving Paradigms in Squamous NSCLC: Referencesover 10 years ago
Evolving Paradigms in Squamous NSCLC: IntroductionAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
FDA Approves Liso-Cel as First CAR T-Cell Therapy for Marginal Zone Lymphoma
3
Lurbinectedin Contributes to Maintenance of Response in ES-SCLC
4
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
5






































